Aquestive Therapeutics, Inc.
AQSTDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jul 31, 2026
17wMarket Overview
Stock performance and key metrics
3 upcoming, 1 past
FDA PDUFA Date AQST-109 (standard)
For Epinephrine Oral Film. NDA filing. Extracted from SEC filing: 8-K
Source2 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Epilepsy
Diazepam Buccal Film 12.5 mg
Epilepsy
Diazepam Buccal Film
Epilepsy
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Epilepsy
DESF
Allergic Reaction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Phase 3 | Epilepsy | - | - |
Diazepam Buccal Film 12.5 mg | Phase 2 | Epilepsy | - | - |
Diazepam Buccal Film | Phase 2 | Epilepsy | - | - |
Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Phase 2 | Epilepsy | - | - |
DESF | Phase 2 | Allergic Reaction | - | - |